$11.32
9.37% yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
US34962G1094
Symbol
FBRX
Sector
Industry

Forte Biosciences Inc Stock price

$11.32
+5.00 79.11% 1M
-16.68 59.57% 6M
-11.39 50.15% YTD
-3.52 23.72% 1Y
-517.43 97.86% 5Y
-4,657.43 99.76% 10Y
-4,657.43 99.76% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.97 9.37%
ISIN
US34962G1094
Symbol
FBRX
Sector
Industry

Key metrics

Market capitalization $74.52m
Enterprise Value $28.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.94
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-45.10m
Free Cash Flow (TTM) Free Cash Flow $-34.52m
Cash position $45.86m
EPS (TTM) EPS $-3.87
Short interest 2.80%
Show more

Is Forte Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Forte Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Forte Biosciences Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Forte Biosciences Inc forecast:

Buy
100%

Financial data from Forte Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
28% 28%
-
- Research and Development Expense 30 30
38% 38%
-
-45 -45
35% 35%
-
- Depreciation and Amortization 0.04 0.04
100% 100%
-
EBIT (Operating Income) EBIT -45 -45
35% 35%
-
Net Profit -44 -44
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Forte Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Forte Biosciences Inc Stock News

Neutral
Business Wire
23 days ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2025 financial results and provided a clinical update. “We are looking forward to reading out the topline data from the FB102 celiac disease trial this quarter. FB102 continues to...
Neutral
Business Wire
2 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update. “2024 was a very productive year with significant progress on the development of FB102, including the completion of the healthy volunteer stud...
Neutral
Business Wire
4 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the L...

Company Profile

Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

Head office United States
CEO Paul Wagner
Employees 14
Founded 2017
Website www.fortebiorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today